---
title: "減重療效比較（GLP-1）"
author: "醫學研究組-Clover Teoh"
date: 2026/01/14
format: 
  html:
    page-layout: full
    toc: false
---
<div style="text-align: center; font-size: 24px; font-weight: bold;">
  <span style="color: red;">
    ！！！ 僅供Cofit及初日診所內部使用，嚴禁外流 ！！！
  </span>
</div>

## 說明
### 使用資料：
- 初日診所 （2025/01/01 - 2026/01/08）
- 初日診所 （2019/09/01 - 2026/01/08）
- 各paper   [（羿清整理的資料）](https://docs.google.com/spreadsheets/d/1KYAXwFJq18Us8SZGVTWGE_kQ0Sft_dnyoqTNJr_QRhU/edit?usp=sharing)

### 初日診所資料納入條件：
- 有參加3次線上團班且3次8週療程間隔時間不超過60天
- 具有完整的W0，W8，W16及W24的體重
- 過重或肥胖的人群（BMI ≧ 24）


## 初日診所和各paper的介入方式整理

|Citation                                        |Source                      |Drug Type                |Intervention                                                                                                                                                 |Population                 |    N|
|:-----------------------------------------------|:---------------------------|:------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------|----:|
|                                                |Genesis (20250101-20260108) |Combined                 |Multimodal (flexible low carb diet)                                                                                                                                                  |Overweight/Obese           |   82|
|                                                |Genesis (20190901-20260108) |Combined                 |Multimodal (flexible low carb diet)                                                                                                                                                   |Overweight/Obese           |  261|
|[SCALE, JAMA Network](https://jamanetwork.com/journals/jama/fullarticle/2428956#note-JOI150093-1)                             |Saxenda 1.8mg               |Liraglutide (GLP-1)      |1.8mg, Calorie restricted (-500kcal) Fat 30% Protein 20%, Carb 50%.  Physical activity 150mins/week                                                          |Overweight/Obese with T2DM |  164|
|[SCALE, JAMA Network](https://jamanetwork.com/journals/jama/fullarticle/2428956#note-JOI150093-1)                             |Saxenda 3.0mg               |Liraglutide (GLP-1)      |3.0mg, Calorie restricted (-500kcal) Fat 30% Protein 20%, Carb 50%.  Physical activity 150mins/week                                                          |Overweight/Obese with T2DM |  324|
|[SUSTAIN 1, Lancet](https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S221385871730013X?returnurl=null&referrer=null)                               |Ozempic (0.5mg)             |Semaglutide (GLP-1)      |                                                                                                                                                             |T2DM                       |  128|
|[SUSTAIN 1, Lancet](https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S221385871730013X?returnurl=null&referrer=null)                               |Ozempic (1.0mg)             |Semaglutide (GLP-1)      |                                                                                                                                                             |T2DM                       |  130|
|[STEP 1, The New England Journal of Medicine](https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed)     |Wegovy      (0.25mg-> 2.4mg)                 |Semaglutide (GLP-1)      |Initiate dose: 0.25mg, increased every 4 week until 2.4mg.  Counseling sessions every 4 week.  Calorie restricteed (-500kcal) Physical activity 150mins/week |Overweight/Obese           | 1306|
|[SURMOUNT 1, The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038#ap2) |Mounjaro 5mg (2.5mg->5mg)               |Tirzepatide (GLP-1+GIP)  |5mg QW, Calorie restricted (-500kcal). Fat 30% Protein 20%, Carb 50% Physical activity 150mins/week.                                                         |Overweight/Obese           |  630|
|[SURMOUNT 1, The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038#ap2) |Mounjaro 10mg (2.5mg->10mg)               |Tirzepatide (GLP-1+GIP)  |does escalation 2.5mg every 4 week, up to 10mg by week 12, 10mg QW, Calorie restricted (-500kcal). Fat 30% Protein 20%, Carb 50% Physical activity 150mins/week.                                                        |Overweight/Obese           |  636|
|[SURMOUNT 1, The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038#ap2) |Mounjaro 15mg (2.5mg->15mg)               |Tirzepatide (GLP-1+GIP)  |does escalation 2.5mg every 4 week, up to 15mg by week 20, 15mg QW, Calorie restricted (-500kcal). Fat 30% Protein 20%, Carb 50% Physical activity 150mins/week.                                                        |Overweight/Obese           |  630|
|[PIONEER 4, Lancet](https://www.sciencedirect.com/science/article/pii/S0140673619312711?via%3Dihub)                               |Rybelsus                    |Oral Semaglutide (GLP-1) |                                                                                                                                                             |T2DM                       |  285|

### SURMOUNT-1 的Mounjaro施打為漸進式增加劑量，如下圖所示：
<img src="Mounjaro_SURMOUNT-1_study_design.png" width="70%">


## 比較初日診所療程與不同GLP-1療程（各paper）的成效
### 減重成效比較 (%)
<iframe src="glp1_weight_loss_pct.html" width="100%" height="600px"></iframe>

### 減重成效比較 (kg)
<iframe src="glp1_weight_loss_kg.html" width="100%" height="600px"></iframe>






### 脂肪量流失佔比和除脂體重流失佔比 (%)

#### 指標定義與計算
**1. 脂肪量流失佔比 (Fat mass loss fraction)** <br>
含義：在減少的總體重當中，「脂肪組織」所佔的比例。

**計算公式：**
$$\text{mean Fat mass loss fraction} = \frac{\text{mean Δ脂肪重量}}{\text{mean Δ總體重}} \times 100\%$$


**2. 除脂體重流失佔比 (Lean mass loss fraction)** <br>
含義：在減少的總體重當中，「瘦肉（肌肉、器官、骨骼等）」所佔的比例。

**計算公式：**
$$\text{mean Lean mass loss fraction} = 100 - \text{mean Fat mass loss fraction}$$

<span style="color: red;">
注：<br>
- Genesis的資料有排除體重增加（weight loss≧ -0.5kg）的人再進行計算。 <br>
- 為了跟paper盡可能公平比較，因paper只能取得mean值，故此處Genesis也先取mean值再計算出Fat mass loss fraction和Lean mass loss fraction。 <br>
- Mounjaro和Wegovy的數據使用較精準的DXA（雙能量X光吸收儀）測量，而Genesis使用BIA（生物電阻抗分析），故比較結果請謹慎參考。<br>
- Mounjaro和Wegovy的具體算法記錄在此[NotebookLM](https://notebooklm.google.com/notebook/a369cb09-0858-4c77-8516-e56e52713c0f)。
</span>

#### 初日診所療程與不同GLP-1療程（各paper）的比較

|Citation|Company| n   | Weeks |Lean Mass Loss Fraction| Fat Mass Loss Fraction|
|:-------|:------|:---:|:-----:|:---------------------:|:---------------------:|
|        |Genesis (20250101-20260108)|82|24|23.3%|76.7%|
|        |Genesis (20190901-20260108)|259|24|22.2%|77.8%|
|[SURMOUNT 1, NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038#ap2)|Mounjaro|160|72|25.7%|74.3%|
|[STEP 1, NEJM](https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) |Wegovy|95|68|40.0%|60.0%|
|[Review](https://pubmed.ncbi.nlm.nih.gov/41465555/)|GLP-1 RA & incretin hormone agonists| | |20–30%| |


<img src="fat_lean_mass_loss_fraction.jpeg" width="85%">

